Neurocrine Biosciences Inc
NASDAQ:NBIX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111.62
153.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Tax Provision
Neurocrine Biosciences Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Tax Provision
-$135.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$63m
|
CAGR 3-Years
68%
|
CAGR 5-Years
48%
|
CAGR 10-Years
30%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$449m
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$739.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-61%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$314.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
3%
|
|
Neurocrine Biosciences Inc
Glance View
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
See Also
What is Neurocrine Biosciences Inc's Tax Provision?
Tax Provision
-135.7m
USD
Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Tax Provision amounts to -135.7m USD.
What is Neurocrine Biosciences Inc's Tax Provision growth rate?
Tax Provision CAGR 5Y
-89%
Over the last year, the Tax Provision growth was -123%.
You don't have any saved screeners yet
